Cargando…

Current status of immunotherapy for non-small cell lung cancer

Nowadays, lung cancer is still the deadliest oncological disease in the world. Among them, non-small cell lung cancer (NSCLC) accounts for 80%∼85% of all lung cancers, and its 5-year survival rate is less than 15%, making the situation critical. In the past decades, despite some clinical advances in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Tao, Xiong, Yilin, Zeng, Yufei, Wang, Yan, Zeng, Jing, Liu, Jie, Xu, Shangfu, Li, Li-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606217/ https://www.ncbi.nlm.nih.gov/pubmed/36313314 http://dx.doi.org/10.3389/fphar.2022.989461

Ejemplares similares

Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations
por: Liu, Wenliang, et al.
Publicado: (2022)

Immunotherapy and targeted therapy for lung cancer: Current status and future perspectives
por: Zulfiqar, Bilal, et al.
Publicado: (2022)

Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer
por: Li, Lingling, et al.
Publicado: (2022)

Targeting glycolysis in non-small cell lung cancer: Promises and challenges
por: Xu, Jia-Qi, et al.
Publicado: (2022)

Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
por: Dong, Jingsi, et al.
Publicado: (2019)

Immunotherapy for a POLE Mutation Advanced Non-Small-Cell Lung Cancer Patient
por: Fu, Yang, et al.
Publicado: (2022)

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives
por: Li, Jia-Xin, et al.
Publicado: (2022)

Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis
por: Lin, Li, et al.
Publicado: (2023)

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series
por: Hu, Yan, et al.
Publicado: (2022)

Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies
por: Gao, Ruo-Lin, et al.
Publicado: (2022)

Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles
por: Cho, Ju Hwan
Publicado: (2017)

Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates
por: Suraya, Ratoe, et al.
Publicado: (2022)

Update on Novel Non-Operative Treatment for Osteoarthritis: Current Status and Future Trends
por: Chen, Tao, et al.
Publicado: (2021)

Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy
por: Yan, Chen, et al.
Publicado: (2022)

Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future
por: Yao, Jiaqi, et al.
Publicado: (2023)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
por: Luo, Xia, et al.
Publicado: (2022)

Prediction of EGFR Mutation Status in Non–Small Cell Lung Cancer Based on Ensemble Learning
por: Feng, Youdan, et al.
Publicado: (2022)

Current Status in Rechallenge of Immunotherapy
por: Hu, Han, et al.
Publicado: (2023)

Current status of iridium-based complexes against lung cancer
por: Yang, Tongfu, et al.
Publicado: (2022)

The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives
por: Rocco, Danilo, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
por: Wan, Xiaomin, et al.
Publicado: (2021)

Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China
por: Li, Hong-Shuai, et al.
Publicado: (2022)

Drug resistance mechanism and reversal strategy in lung cancer immunotherapy
por: Xu, Yishi, et al.
Publicado: (2023)

Elevated N-Glycosylation Contributes to the Cisplatin Resistance of Non-Small Cell Lung Cancer Cells Revealed by Membrane Proteomic and Glycoproteomic Analysis
por: Zeng, Wenjuan, et al.
Publicado: (2021)

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
por: Huang, Zhangfeng, et al.
Publicado: (2020)

Sanguisorba officinalis L. suppresses non-small cell lung cancer via downregulating the PI3K/AKT/mTOR signaling pathway based on network pharmacology and experimental investigation
por: Li, Hong, et al.
Publicado: (2022)

Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents
por: Wang, Yan, et al.
Publicado: (2023)

Docetaxel-Loaded Novel Nano-Platform for Synergistic Therapy of Non-Small Cell Lung Cancer
por: Feng, Xing, et al.
Publicado: (2022)

Recent progress in targeted therapy for non-small cell lung cancer
por: Xiao, Yanxia, et al.
Publicado: (2023)

Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions
por: Wang, Yifan, et al.
Publicado: (2018)

Corrigendum: Docetaxel-loaded novel nano-platform for synergistic therapy of non-small cell lung cancer
por: Feng, Xing, et al.
Publicado: (2022)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China
por: Qiao, Liu, et al.
Publicado: (2021)

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
por: Zhou, Dongchu, et al.
Publicado: (2022)

A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma
por: Zhang, Hai-Bo, et al.
Publicado: (2023)

METTL7B Is Required for Cancer Cell Proliferation and Tumorigenesis in Non-Small Cell Lung Cancer
por: Liu, Dongcheng, et al.
Publicado: (2020)

Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives
por: Yang, Ying, et al.
Publicado: (2023)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
por: Shi, Chunyan, et al.
Publicado: (2022)

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer
por: Luo, Xia, et al.
Publicado: (2022)

EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors
por: Xu, Haiyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_23a836bb69082hm08oko6mdufk